Expertise in
6
conditions

Dr. Jakob W. Begun

Gastroenterology
55 Fruit St, Balke 4, 
Boston, MA 
Expertise in
6
conditions
55 Fruit St, Balke 4, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jakob Begun is a Gastroenterologist in Boston, Massachusetts. Dr. Begun is highly rated in 6 conditions, according to our data. His top areas of expertise are Viral Gastroenteritis, Colitis, Ulcerative Colitis, Hemorrhagic Proctocolitis, and Endoscopy.

His clinical research consists of co-authoring 103 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gastroenterology
Licenses
Internal Medicine in MA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

55 Fruit St, Balke 4, Boston, MA 02114

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
Enrollment Status: Terminated
Publish Date: March 31, 2022
Intervention Type: Drug, Other
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
Enrollment Status: Terminated
Publish Date: June 14, 2021
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 305)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 305)
Enrollment Status: Terminated
Publish Date: April 29, 2021
Intervention Type: Other, Biological
Study Phase: Phase 3
View 7 Less Clinical Trials

100 Total Publications

Pro-inflammatory macrophages transporting gut-derived bacterial DNA drive autoimmune arthritis in spondyloarthropathy.
Pro-inflammatory macrophages transporting gut-derived bacterial DNA drive autoimmune arthritis in spondyloarthropathy.
Journal: JCI insight
Published: August 05, 2025
Similar Doctors
Gilaad G. Kaplan
Expertise in
18
conditions
Dr. Gilaad G. Kaplan
Gastroenterology
Expertise in
18
conditions
Dr. Gilaad G. Kaplan
Gastroenterology
Massachusetts General Hospital, 55 Fruit Street, 
Boston, MA 
 (0.1 miles away)
617-726-3673
Languages Spoken:
English

Gilaad Kaplan is a Gastroenterologist in Boston, Massachusetts. Dr. Kaplan is highly rated in 18 conditions, according to our data. His top areas of expertise are Viral Gastroenteritis, Crohn's Disease, Colitis, Endoscopy, and Colonoscopy.

Expertise in
14
conditions
Dr. Hamed Khalili
Gastroenterology
Expertise in
14
conditions
Dr. Hamed Khalili
Gastroenterology

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
 (0.1 miles away)
617-726-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Hamed Khalili is a Gastroenterologist in Boston, Massachusetts. Dr. Khalili is highly rated in 14 conditions, according to our data. His top areas of expertise are Ulcerative Colitis, Crohn's Disease, Lymphocytic Colitis, Endoscopy, and Colonoscopy. Dr. Khalili is currently accepting new patients.

Ashwin N. Ananthakrishnan
Expertise in
14
conditions
Dr. Ashwin N. Ananthakrishnan
Gastroenterology
Expertise in
14
conditions
Dr. Ashwin N. Ananthakrishnan
Gastroenterology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (0.1 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ashwin Ananthakrishnan is a Gastroenterologist in Boston, Massachusetts. Dr. Ananthakrishnan is highly rated in 14 conditions, according to our data. His top areas of expertise are Ulcerative Colitis, Crohn's Disease, Viral Gastroenteritis, Colonoscopy, and Endoscopy. Dr. Ananthakrishnan is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Begun's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile